Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Broadens Technology Deal with BioMerieux to Cancer Diagnostics

NEW YORK, April 5 (GenomeWeb News) - Affymetrix has expanded an existing technology agreement with diagnostics company BioMerieux to include further disease areas, the companies said today.

 

Under the agreement, BioMerieux, of Marcy L'Etoile, France, has non-exclusive rights to Affymetrix's GeneChip technology, including future improvements, to develop and market in vitro diagnostics for breast cancer. The company also has the option to broaden this agreement to other cancers.

 

Under an agreement from late 2003, BioMerieux has had the right to use Affy's GeneChip technology to develop tests for virulence factors, bacterial strain typing, sepsis diagnosis, hepatitis C, as well as respiratory and central nervous system infectious panels.

 

The companies did not disclose financial terms of the new agreement.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.